ChartMill · Aug 27, 2026
Boston Scientific (NYSE:BSX) Stands Out as a Quality Investment
Boston Scientific passes the Caviar Cruise quality screen with strong ROIC, cash conversion, and attractive valuation.
NYSE · BSX
Boston Scientific Corporation
Healthcare · Medical - Devices
$46.84
Up+$0.17 (+0.36%)
Updated Aug 30, 2026, 5:48 AM
SID Score
5.4/10
Composite research score
Smart Money
82/100
Bullish
- Market cap
- 135.98B
- P/E ratio
- 48.75
- Dividend yield
- 0.00%
- 52-week range
- $42.20 – $100.90
- Volume
- 17.15M
- Avg. volume
- 9.87M
Price performance
BSX price history
1M range · 20 trading sessions · Daily adjusted prices
BSX closed at $46.84 after 20 trading sessions, down 3.28% for the selected period.
- Last close
- $46.84
- Period change
- -3.28%
- Period low
- $46.67
- Period high
- $52.01
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Aug 28, 2026 | $46.85 | $47.22 | $46.50 | $46.84 | 17.15M |
| Aug 27, 2026 | $48.00 | $48.07 | $46.61 | $46.67 | 16.28M |
| Aug 26, 2026 | $47.00 | $48.54 | $46.90 | $48.17 | 36.58M |
| Aug 25, 2026 | $48.79 | $50.04 | $48.54 | $49.86 | 17.37M |
| Aug 24, 2026 | $50.29 | $50.38 | $48.77 | $49.01 | 22.03M |
| Aug 21, 2026 | $49.22 | $50.90 | $49.01 | $50.37 | 35.99M |
| Aug 20, 2026 | $51.64 | $51.80 | $49.36 | $49.37 | 20.39M |
| Aug 19, 2026 | $50.80 | $52.56 | $50.66 | $52.01 | 16.83M |
| Aug 18, 2026 | $52.38 | $52.53 | $50.45 | $50.47 | 11.72M |
| Aug 17, 2026 | $51.71 | $52.065 | $51.24 | $51.43 | 18.15M |
| Aug 14, 2026 | $52.83 | $52.9894 | $51.698 | $51.83 | 16.3M |
| Aug 13, 2026 | $51.57 | $52.335 | $51.22 | $51.69 | 15.7M |
| Aug 12, 2026 | $50.50 | $51.74 | $50.02 | $51.42 | 20.67M |
| Aug 11, 2026 | $50.27 | $51.50 | $50.13 | $51.19 | 13.45M |
| Aug 10, 2026 | $49.54 | $50.82 | $49.54 | $50.46 | 18.99M |
| Aug 7, 2026 | $49.50 | $50.12 | $49.06 | $49.31 | 11.45M |
| Aug 6, 2026 | $49.23 | $50.16 | $48.875 | $49.30 | 21.4M |
| Aug 5, 2026 | $49.47 | $49.4863 | $47.10 | $47.74 | 16.51M |
| Aug 4, 2026 | $48.11 | $49.21 | $47.98 | $49.09 | 21.57M |
| Aug 3, 2026 | $47.82 | $48.92 | $47.50 | $48.43 | 20.38M |
Latest BSX news
The latest Smart Investors Daily articles mentioning BSX.
Stock researchCompany · Overview
BSX research
Overview
Company profile and research snapshot.
Company profile
Boston Scientific produces less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, kidney stone management, cardiac rhythm management, catheter-directed ultrasound imaging, upper gastrointestinal tract diagnostics, interventional oncology, neuromodulation for chronic pain, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for roughly 36% of the firm's total sales.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- Buy
- Average target
- $127.00
- Implied upside
- —
- Analysts
- 24
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 25, 2026 | TD Cowen | Buy | — |
| Jul 31, 2026 | Argus Research | Hold | — |
| Jul 30, 2026 | Evercore ISI Group | Outperform | — |
| Jul 30, 2026 | Wells Fargo | Equal-Weight | — |
| Jul 30, 2026 | UBS | Buy | — |
News briefing
No generated briefing is available yet.
CNBC · Aug 26, 2026
Thursday's big stock stories: What’s likely to move the market in the next trading session
The S&P 500 closed Wednesday not too far from where it began as investors waited for Nvidia to post its results. The chipmaker's stock was higher after hours.
Yahoo · Aug 26, 2026
Atrial Fibrillation Treatment Devices Market Trends and Forecast, 2035 | Includes Profiles of Abbott, AtriCure, Boston Scientific, Johnson & Johnson, and Medtronic
Opportunities center on pulsed field ablation, advanced mapping catheters and LAAC implants, driven by aging populations and demand for safer, drug-free care. Asia-Pacific expansion, ambulatory procedures, improving reimbursement and regulatory support offer further growth. Atrial Fibrillation Treatment Devices Market Atrial Fibrillation Treatment Devices Market Dublin, Aug. 26, 2026 (GLOBE NEWSWIRE) -- The "Atrial Fibrillation Treatment Devices Market by Type of Device, Type of Technology, End
Yahoo · Aug 26, 2026
Boston Scientific shares fall after cybersecurity incident disrupts operations
Boston Scientific (NYSE:BSX) disclosed on Tuesday that a cybersecurity incident has affected some of its information technology systems, disrupting parts of the medical device company’s operations. Shares of Boston Scientific fell 4% in premarket trading on Wednesday following the disclosure.
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
